Hereditary Angioedema Therapeutic Market
Hereditary Angioedema Therapeutic Market size was valued at USD million in 2018 and is expected to reach at USD million by 2026 at a CAGR of over forecast period 2019-2026. Increasing cases of hereditary angioedema (HAE) globally is a mainly driving the Hereditary Angioedema Therapeutic market. According to the National Organization for Rare Disorders (NORD), about 1-9 people per 100,000 population are affected by the condition. The actual number of individuals with the condition are significantly higher due to under-reporting and misdiagnosis.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. In 2018, there were approximately 422,700 prevalent cases of hereditary angioedema worldwide, and forecasts that number to increase to K prevalent cases by 2026. This increasing cases of hereditary angioedema (HAE) is driving the hereditary angioedema (HAE) therapeutics market. Lack of awareness about HAE International (HAE), an international hereditary angioedema patient organization, is a major reason for misdiagnosis, which in turn, leads to inadequate treatment being provided to patients. The hereditary angioedema market is segmented into such as drug class, route of administration, by treatment type, and by region. By drug class market is further segmented into four other categories such as kallikrein inhibitor, selective bradykinin B2 receptor antagonist, C1 esterase inhibitor, and others. C1 esterase inhibitor segment is expected to exhibit highest market share at a CAGR of XX% over forecast period. By geography, hereditary angioedema market is segmented into APAC, North America, Europe, MEA& Africa and Latin America. North America accounted for a leading share in the market in terms of revenue in 2018 owing to new product launches by major players, better reimbursement scenario, and a well-developed healthcare infrastructure. Growing patient awareness levels, coupled with launch of novel therapies for hereditary angioedema management, is expected to drive the market in the region. Key players operating in hereditary angioedema market are BioCryst Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Pharming Group N.V., CSL Limited, Shire Plc., Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., and KalVista Pharmaceuticals, Inc. These players are entering into distribution agreements in order to increase their market share boost and their presence across different geographies. The objective of the report is to present comprehensive analysis of hereditary angioedema market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding hereditary angioedema market dynamics, structure by analysing the market segments, and project the global critical communication market size. Clear representation of competitive analys
About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healt..